EP
RLAY icon

Eversept Partners’s Relay Therapeutics RLAY Stock Holding History

Eversept Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.69M Sell
270,705
-218,432
-45% -$1.95M 0.14% 81
2025
Q4 		$4.14M Buy
489,137
+10,081
+2% +$71.9K 0.21% 74
2025
Q3 		$2.5M Sell
479,056
-54,353
-10% -$207K 0.17% 62
2025
Q2 		$1.85M Buy
+533,409
New +$1.59M 0.17% 54

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Eversept Partners's RLAY Position: Q1 2026 in Review

Eversept Partners reduced its Relay Therapeutics (RLAY) stake by 45% in Q1 2026, selling an estimated $1.95M and leaving 270,705 shares worth $2.69M. The position accounts for 0.14% of the portfolio, ranked #81.

Eversept Partners first reported a position in RLAY in Q2 2025 and has held it in 4 quarters since. The position peaked at $4.14M in Q4 2025. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Eversept Partners held 270,705 shares of Relay Therapeutics worth $2.69M as of Q1 2026.
  • Eversept Partners sold 218,432 Relay Therapeutics shares in Q1 2026, an estimated $1.95M.
  • Relay Therapeutics made up 0.14% of Eversept Partners's portfolio in Q1 2026, its #81 holding.
  • Eversept Partners first reported a position in Relay Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Eversept Partners's Relay Therapeutics position peaked at $4.14M in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.